RxDoctor Payments Data

Jose Ruben Ayala, MD

Family Medicine · El Paso, TXNPI 1376743518

Payments from drug & device makers

$2,919in general payments, 2019–2025

Across 110 payments — averaging $26.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$617
  • AstraZeneca$485
  • GE HealthCare$407
  • Lilly USA, LLC$329
  • Bayer$171
  • AbbVie$150
  • plus $760 from 14 others

What the payments were for

  • Travel & lodging$40714%
  • Food & beverage$2,51286%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,919 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$124,096
Medicare patients
320
Services billed
1,633

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin166$212,057
FarxigaDapagliflozin Propanediol163$193,848
OzempicSemaglutide81$156,920
JanuviaSitagliptin Phosphate106$134,595
TrulicityDulaglutide38$96,565
EliquisApixaban71$90,294
TradjentaLinagliptin56$49,508
LinzessLinaclotide31$39,388
XifaxanRifaximin12$37,252
XareltoRivaroxaban25$34,604
MounjaroTirzepatide21$32,865
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog27$29,810
RybelsusSemaglutide11$28,788
Janumet XrSitagliptin Phos/Metformin Hcl20$28,135
JanumetSitagliptin Phos/Metformin Hcl33$23,279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$105$261,565222 claims
AstraZenecaFarxiga, Brilinta, Symbicort$485$206,675188 claims
Novo NordiskOzempic, Rybelsus$617$185,70892 claims
Lilly USA, LLCTrulicity, Mounjaro$329$129,43059 claims
PfizerEliquis$65$90,29471 claims
AbbVieLinzess, Synthroid$150$45,589115 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$32$43,44023 claims
Johnson & JohnsonXarelto$110$34,60425 claims
GSKAnoro Ellipta, Arexvy$122$23,29339 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →